Validation of PHQ-2 and PHQ-9 to Screen for Major Depression in the Primary Care Population

Arroll, Bruce; Goodyear‐Smith, Felicity; Crengle, Sue; Gunn, Jane; Kerse, Ngaire; Fishman, Tana; Falloon, Karen; Hatcher, Simon

doi:10.1370/afm.1139

Cited by 1,052 publications

(840 citation statements)

References 16 publications

Supporting

Mentioning

768

Contrasting

Unclassified

Order By: Relevance

“…In a previous study of the general primary care population, 11% of individuals were found to have a PHQ-2 score-3, 15 and the average POMS-B total mood disturbance score in a control population was reported to be 23.5. 23 For both of these assessments, the MPN population scores in the current study indicated a greater prevalence of mood symptoms.…”

Section: Discussionmentioning

confidence: 94%

Comprehensively understanding fatigue in patients with myeloproliferative neoplasms

Scherber

Kosiorek

Senyak

et al. 2015

Cancer

View full text Add to dashboard Cite

BACKGROUND Patients with myeloproliferative neoplasms (MPNs) experience a high persistence, prevalence, and severity of fatigue. There is currently only limited information regarding factors that contribute to fatigue in patients with MPNs. METHODS A 70‐item, Internet‐based survey regarding fatigue was developed by MPN investigators and patients/advocates and hosted by the Mayo Clinic Survey Research Center. RESULTS Fatigue was found to be prevalent and severe among international survey respondents (1788 respondents). Higher body mass index (P<.001), current use of alcohol (P<.001), and current tobacco use (P = .0025) were found to be significantly associated with greater fatigue. Moderate/severe fatigue was present more frequently in those individuals who did not exercise compared with those who reported exercising at least once per week (P<.001). Medical comorbidities found to be significantly associated with greater fatigue included restless leg syndrome (P = .006), diabetes mellitus (P = .045), fibromyalgia (P < 0.001), chronic fatigue syndrome (P = .006), and chronic kidney disease (P = .02). Current use of antidepressants (P<.001), antihistamines (P = .0276), antianxiety medications (P = .0357), and prescription pain medications (P<.001) were found to be associated with worsened fatigue. Nearly 25% of respondents scored > 2 on the Patient Health Questionnaire, indicating a high probability of depression. Higher Brief Fatigue Inventory score, Myeloproliferative Neoplasm Total Symptom Score, and individual symptom items were all associated with a higher likelihood of depressive symptoms (P<.0001). CONCLUSIONS The management of fatigue should be multifactorial, with a comprehensive assessment and treatment plan to address all modifiable fatigue etiologies. Patients with MPNs likely have a higher prevalence of mood disturbances compared with the general population, suggesting the need to assess and intervene in this domain. Cancer 2016;122:477–485. © 2015 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 94%

Comprehensively understanding fatigue in patients with myeloproliferative neoplasms

Scherber

Kosiorek

Senyak

et al. 2015

Cancer

View full text Add to dashboard Cite

show abstract

“…(34,35) Due to its brevity, the recommendation is to use the PHQ-2 simply as a screening tool for major depression and not for assessing disease severity. Among primary care doctors, (35) some recommend using a threshold score ≥ 2 (instead of ≥ 3) to improve sensitivity. Patients who obtain a score ≥ 2 should proceed to the nine-item Patient Health Questionnaire-9 (PHQ-9).…”

Section: How Do I Screen For Major Depression In Primary Care?mentioning

confidence: 99%

Major depression in primary care: making the diagnosis

Ng¹,

How²,

Ng³

2016

smedj

View full text Add to dashboard Cite

“…13 Our tobacco registry form included depression screening prompts, which also were included in the other chronic disease registries. 14 We have not reported on this variable because we could not examine individual contributions from this registry.…”

Section: Discussionmentioning

confidence: 99%

Patient Care Outcomes of a Tobacco Use Registry in an Academic Family Practice

Ripley‐Moffitt

Neutze

Gwynne

et al. 2015

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

Purpose: While the potential benefit of a chronic disease registry for tobacco use is great, outcome reports have not been generated. We examined the effect of implementing a tobacco use registry, including a decision support tool, on treatment outcomes within an academic family medicine clinic.Methods: A chart review of 200 patients who smoked and attended the clinic before and after registry implementation assessed the number of patients with clinic notes documenting (1) counseling for tobacco use, (2) recommendations for cessation medication, (3) a set quit date, (4) referrals to the onsite Nicotine Dependence Program (NDP) and/or QuitlineNC, and (5) pneumococcal vaccine. Data from the NDP, QuitlineNC, and clinic billing records before and after implementation compared the number of clinic-generated QuitlineNC fax referrals, new scheduled appointments for the NDP, and visits coded for tobacco counseling reimbursement.Results: Significant increases in documentation occurred across most chart review variables. Significant increases in the number of clinic-generated fax referrals to QuitlineNC (from 27 to 96), initial scheduled appointments for the NDP (from 84 to 148), and coding for tobacco counseling (from 101 to 287) also occurred when compared with total patient visits during the same time periods. Patient attendance at the NDP (52%) and acceptance of QuitlineNC services (31%) remained constant. Tobacco use remains the leading cause of preventable disease and death in the United States, and smoking accounts for nearly half a million premature deaths annually.1 Because tobacco abstinence reduces tobacco-related morbidity and mortality, treating tobacco use should be a key component of providing high-quality health care to patients. Research has demonstrated the critical importance of the physician's role in tobacco use treatment. 2Clinical practice guidelines recommend that tobacco use be addressed at each office visit with brief interventions using the "5 As" (ask about tobacco use; advise cessation; assess willingness to quit, assist in a quit attempt; and arrange follow-up), combined with offers of pharmacotherapy. 3 Meta-analyses have found that brief interventions double-and the use of pharmacotherapy triples-a patient's chances of successfully quitting. 3Substantial progress has been made in tobacco use treatment interventions (eg, quit lines, medications, and feedback systems). Unfortunately, rates of counseling and offers of medication remain low. 4 This article was externally peer reviewed.

show abstract

Validation of PHQ-2 and PHQ-9 to Screen for Major Depression in the Primary Care Population

Cited by 1,052 publications

References 16 publications

Comprehensively understanding fatigue in patients with myeloproliferative neoplasms

Comprehensively understanding fatigue in patients with myeloproliferative neoplasms

Major depression in primary care: making the diagnosis

Patient Care Outcomes of a Tobacco Use Registry in an Academic Family Practice

Contact Info

Product

Resources

About